Proton Pump Inhibitors Overused Worldwide

This article originally appeared here.
Share this content:
Proton Pump Inhibitors Overused Worldwide
Proton Pump Inhibitors Overused Worldwide

WEDNESDAY, Sept. 20, 2017 (HealthDay News) -- Proton pump inhibitors (PPIs) are overused worldwide, with wide variation seen in the extent of inappropriate use, according to research published online Sept. 11 in the Journal of Clinical Pharmacy and Therapeutics.

Mark Naunton, Ph.D., from the University of Canberra in Australia, and colleagues analyzed data from the Australian Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme to determine PPI usage in Australia. A literature review was conducted, and the authors examined the trend of reported PPI appropriate use across international studies.

The researchers found that from 2002 to 2010 there was an increase in PPI use in Australia, followed by a gradual decrease. There was wide variation in estimates of the extent of inappropriate use in the international literature (11 to 84 percent). From 2000 to 2016 there was little change in the extent of appropriate PPI use reported in 34 international studies. Patient-centered deprescribing, academic detailing, educational programs, and safety notifications were interventions for addressing inappropriate use.

"Ongoing education and awareness campaigns for health professionals and patients, including electronic reminders at the point of prescribing, are strategies that have potential to reduce PPI use in individuals who do not have an evidence-based clinical indication for their long-term use," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Lyme-Bearing Ticks More Widespread in U.S. Than Thought

Disease-carrying ticks were detected in 83 counties where they'd never been found before

Availability of Generic Antivirals for Hepatitis B Increasing

Availability of Generic Antivirals for Hepatitis B Increasing

Drop in median price of WHO-prequalified generic tenofovir from $208 to $32 from 2004 to 2016

Visual Function Deficits Up in Developmental Dyslexia

Visual Function Deficits Up in Developmental Dyslexia

Increased prevalence of deficits in visual function versus typically developing school-age children

is free, fast, and customized just for you!




Already a member?

Sign In Now »